Edition:
India

Spero Therapeutics Inc (SPRO.OQ)

SPRO.OQ on NASDAQ Stock Exchange Global Select Market

10.50USD
8 Dec 2017
Change (% chg)

$-0.01 (-0.10%)
Prev Close
$10.51
Open
$10.45
Day's High
$11.00
Day's Low
$10.45
Volume
18,504
Avg. Vol
--
52-wk High
$15.39
52-wk Low
$9.94

Summary

Name Age Since Current Position

Milind Deshpande

60 2014 Independent Chairman of the Board

Ankit Mahadevia

37 2015 President, Chief Executive Officer, Director

Joel Sendek

49 2017 Chief Financial Officer

Cristina Larkin

47 2017 Chief Operating Officer and Chief Commercial Officer

Timothy Keutzer

50 2017 Senior Vice President - Development

Thomas Parr

63 2014 Chief Scientific Officer

Stephen Garbacz

57 2015 Vice President - Finance and Operations

Casper Breum

50 2015 Independent Director

Jean-Francois Formela

61 2013 Independent Director

Vikas Goyal

38 2013 Independent Director

Frank Thomas

47 2017 Independent Director

Patrick Vink

54 2015 Independent Director

Sharon Klahre

2017 IR Contact Officer

Biographies

Name Description

Milind Deshpande

Dr. Milind S. Deshpande, Ph.D. Independent Chairman of the Board of the Company. Dr. Deshpande joined Achillion Pharmaceuticals, Inc. in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004 and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President of Research and Development in October 2010. In May 2013, Dr. Deshpande was appointed President and Chief Executive Officer of Achillion and joined its board of directors on which he continues to serve. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.

Ankit Mahadevia

Dr. Ankit Mahadevia M.D., is President, Chief Executive Officer, Director of Spero Therapeutics, LLC. He has served as our Chief Executive Officer and President since March 2015 and has been a member of our board of directors since September 2013. He co-founded the company in 2013. Prior to joining us, Dr. Mahadevia was a Venture Partner in the life sciences group at Atlas Venture in Cambridge, Massachusetts, where he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Synlogic Therapeutics and Translate Bio. He has led three of these companies as acting or full-time CEO. Prior to joining Atlas Venture in 2008, Dr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. Dr. Mahadevia holds an M.D. from the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University.

Joel Sendek

Mr. Joel D. Sendek is Chief Financial Officer of the Company. Mr. Sendek has more than 25 years of experience in the life sciences sector, including 18 years as a senior sell-side research analyst covering biotechnology. Prior to joining us, Mr. Sendek was the Chief Financial Officer at Forward Pharma A/S since August 2014. As an analyst, he served as a Managing Director at Stifel Financial Corp. from January 2012 to July 2014, where he led the firm’s healthcare equity research group, and previously he was a Managing Director at Lazard Ltd. since January 2000, where he established the firm’s healthcare equity research effort. Prior to his career in equity research, Mr. Sendek worked as a Senior Director of Corporate Development at Progenics Pharmaceuticals, Inc. and as an investment banking analyst at Goldman, Sachs & Co. Mr. Sendek holds a B.A. in Biochemistry from Rice University.

Cristina Larkin

Ms. Cristina Larkin is Chief Operating Officer and Chief Commercial Officer of the Company. Ms. Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin. Prior to joining us, Ms. Larkin founded CLC Insights, LLC. Prior to that, since 2004, she worked at Actavis, plc, formerly Forest Laboratories, Inc., where she served in various positions, including Assistant Vice President from 2014 to 2015. During that time, Ms. Larkin led the commercial hospital antibiotic franchise team and was responsible for the U.S. launch and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in several strategic ventures, including the out-licensing of ceftaroline to AstraZeneca plc and the acquisition of Durata. From 1996 to 2002, Ms. Larkin served in various roles at Ortho-McNeil Pharmaceutical, LLC. Ms. Larkin received a bachelor’s degree from Florida State University.

Timothy Keutzer

Mr. Timothy Keutzer is Senior Vice President - Development of the Company. He had served as our Vice President of Development since September 2015. He has over 20 years of experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining us, Mr. Keutzer was employed by Cubist Pharmaceuticals, Inc. from 2008 to 2015. He was Vice President of Program and Portfolio Management from 2014-2015. While at Cubist, he was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3 clinical trials, and was approved in the United States in December 2014. Prior to that role, he also led several of Cubist’s in-licensed development programs, and also led the commercial supply chain for Cubicin. His experience before Cubist spans the drug development continuum across multiple drug classes, and includes preclinical PK/PD and clinical operations at Genetics Institute, Inc., as well as global strategic marketing and program management at Wyeth. Mr. Keutzer began his career in contract toxicology laboratories. He studied English and microbiology at the University of Kentucky.

Thomas Parr

Dr. Thomas R. (Tom) Parr, Ph.D. is Chief Scientific Officer of the Company. He has more than 26 years of drug discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining us, from 2012 to 2014, Dr. Parr was the Chief Scientific Officer at Fedora Pharmaceuticals, Inc. where the company moved novel diazabicyclooctane beta-lactramase inhibitors toward development partnerships. Prior to Fedora, he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. Dr. Parr earned his Ph.D. from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.

Stephen Garbacz

Mr. Stephen Garbacz is Vice President of Finance and Operations of the Company. He has over 20 years of senior finance experience in biotechnology and consumer products. Prior to joining us, he was the Executive Director at Epizyme, Inc. where he played a leading role in that company’s IPO. Before joining Epizyme in 2012, Mr. Garbacz held senior financial positions at Biogen, Inc., including Controller of International (based in Switzerland), Director of Operations and Technology and Director of Accounting. Mr. Garbacz has also held senior financial positions at Kraft Foods Group, Inc., including mergers and acquisitions, treasury, financial planning and analysis, and international. He has an M.B.A. in Finance from the Stern Graduate School of Business at New York University and a B.S. in Economics from George Mason University.

Casper Breum

Mr. Casper Breum is Independent Director of the Company. Mr. Breum is a Senior Partner at Lundbeckfond Ventures, where he has been since 2009. Previously, Mr. Breum was Chief Executive Officer of Ilochip A/S, a venture-backed company focused on the development of diagnostic biochips. Prior to Ilochip, Mr. Breum held different positions at H. Lundbeck A/S, most recently in corporate business development and strategy. While working at H. Lundbeck A/S, he was a member of the board of directors of Lundbeckfond and Lundbeckfond Invest A/S, the main shareholder of H. Lundbeck A/S and ALK-Abello A/S, as an employee representative. Mr. Breum is currently a member of the board of directors of Atox Bio Inc., Biom’Up SA, Dysis Medical Ltd., and Laboratoris Sanifit, S.L. Mr. Breum obtained an MSc in Organic Chemistry and an M.B.A. in Management of Technology, both from the Technical University of Denmark.

Jean-Francois Formela

Dr. Jean-Francois Formela is Independent Director of the Company. Mr. Formela is currently a partner at Atlas Venture and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. Dr. Formela joined Atlas Venture in 1993 to build its U.S. life sciences franchise. Prior to joining Atlas, he worked at Schering-Plough Corporation, where he directed U.S. Phase 4 clinical trials in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Dr. Formela began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Dr. Formela serves as chair of the board of directors of IFM Therapeutics, and serves on the boards of directors of Intellia Therapeutics, F-Star Biotechnology Ltd., Kyn Therapeutics, Inc. and Translate Bio, which he co-founded. Dr. Formela received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

Vikas Goyal

Mr. Vikas Goyal is Independent Director of the Company. Mr. Goyal is currently a Principal at S.R. One, Limited, the corporate venture capital arm of GlaxoSmithKline plc, in Cambridge, Massachusetts, where he manages investments in innovative drug discovery and development companies. He joined S.R. One, Limited in January 2011. Prior to joining S.R. One, Limited, Mr. Goyal was a consultant in the pharmaceutical and medical products practice at McKinsey and Company, a co-founder of Extera Partners, where he advised public and private life sciences companies, and a business development manager at Infinity Pharmaceuticals, Inc. Over his career, Mr. Goyal has supported business and corporate development activities for nearly 50 large and small public, venture-backed, and angel funded life science companies. He received his B.A. in Neurobiology from Harvard University and his M.B.A. in Health Care Management from the Wharton School of the University of Pennsylvania.

Frank Thomas

Mr. Frank E. Thomas is Independent Director of the Company. Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a publicly traded commercial-stage pharmaceutical company, from April 2015 to April 2017, and previously served as AMAG’s Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to joining AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015 and currently serves as a member of the board of directors of Zafgen, Inc., a public biopharmaceutical company, which he joined in June 2014. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.

Patrick Vink

Dr. Patrick Vink is Independent Director of the Company. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and non-executive board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc. Most recently he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company’s profit and loss. He joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink has served on the board of directors of Concordia International Corp., Santhera Pharmaceuticals Ag. and Arch Biopartners.

Sharon Klahre